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Available online 10 April 2019Background:Multiple Sclerosis (MS) results from genetic predisposition and environmental variables, including
elevated Body Mass Index (BMI) in early life. This study addresses the effect of BMI on the epigenome of mono-
cytes and disease course in MS.
Methods: Fifty-four therapy-naive Relapsing Remitting (RR)MSpatientswith high and normal BMI received clin-
ical andMRI evaluation. Blood samples were immunophenotyped, and processed for unbiased plasma lipidomic
proﬁling and genome-wide DNA methylation analysis of circulating monocytes. The main ﬁndings at baseline
were validated in an independent cohort of 91 therapy-naïve RRMS patients. Disease course was evaluated by
a two-year longitudinal follow up and mechanistic hypotheses tested in human cell cultures and in animal
models of MS.
Findings: Higher monocytic counts and plasma ceramides, and hypermethylation of genes involved in negative
regulation of cell proliferationwere detected in the high BMI group ofMS patients compared to normal BMI. Cer-
amide treatment of monocytic cell cultures increased proliferation in a dose-dependent manner and was
prevented by DNAmethylation inhibitors. The high BMI group of MS patients showed a negative correlation be-
tween monocytic counts and brain volume. Those subjects at a two-year follow-up showed increased T1 lesion
load, increased disease activity, and worsened clinical disability. Lastly, the relationship between body weight,
monocytic inﬁltration, DNA methylation and disease course was validated in mouse models of MS.
Interpretation: High BMI negatively impacts disease course in Multiple Sclerosis by modulating monocyte cell
number through ceramide-induced DNA methylation of anti-proliferative genes.
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It is becoming increasingly evident that the growing “epidemic” of
fast food and processed food consumption in the United States and its
association with increased Body Mass Index (BMI) is impacting the
overall health status of the population [1–3]. Alarming statistics have re-
cently demonstrated a link between emergency room visits and BMI,
not just for obese patients, but also for overweight individuals [4,5].
While much of the discussion on the exponentially increasing healththe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research In Context
Evidence before this study
Multiple Sclerosis (MS) defines a neurological condition character-
ized by inflammatory demyelination and axonal/neuronal degener-
ation, which is thought to result from the integration of genetic
predisposition and environmental variables, and clinically pro-
gresses towards permanent disability. Previous studies on high
BodyMass Index (BMI) in childhood as a risk factor for the disease
suggest that BMI can induce long term effects, but the underlying
mechanisms and impact on disease course remain elusive.
Added value of this study
This study investigates the effect of BMI on the epigenome of
monocytes sorted from the blood of recently diagnosed therapy
naïve MS patients. By conducting blinded immunophenotyping,
and genome-wide DNA methylation analysis, we identified DNA
hypermethylation of genes negatively regulating proliferation as
part of themechanism responsible for the higher numbers of circu-
lating monocytes in MS patients with high BMI. Unbiased
lipidomic profiling of plasma samples revealed the presence of
more abundant ceramide species in MS patients with high BMI,
which likely reflected the synergy between de novo synthesis
from dietary fats and recycling of damaged lipids due to the dis-
ease process. Cell-based approaches in cultured monocytes fur-
ther revealed the nuclear localization of uptaken ceramides and
validated their role as inducers of DNA hypermethylation on anti-
proliferative genes, resulting in increased cell counts. Finally, we
report an association between increased monocyte numbers, re-
duced brain volume and worsened clinical disability at the two-
year follow-up in MS patients with high BMI; a finding that was
reproduced in animal models of MS. Overall, these data identify
the BMI-dependent increase of specific ceramide species as an im-
portant determinant of disease course in MS, acting, at least in
part, by modulating the epigenome of monocytes.
Implications of all the available evidence
The reported DNA methylation changes caused by ceramides in
monocytes and previous work on neurotoxic ceramides highlight
the concept that the long-lasting deleterious effect of BMI on MS
disease course could be hampered bymodification of lifestyle var-
iables, such as diet. It is suggested that plasma ceramide levels in
MS patients are derived not only from the degradation of myelin
lipids but also from the dietary intake of saturated fats. Future
studies are needed to evaluate dietary guidelines limiting specific
saturated fatty acids that can be used for ceramide synthesis
and possibly define DNA methylation inhibitors as potential sup-
plementary therapeutic strategies.
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diovascular disorders and metabolic syndromes [6], a growing body of
literature suggests an impact of BMI on a wide variety of other health
conditions, including neurological disorders, such as Alzheimer's dis-
ease [7–9], Parkinson's disease [10,11] and Multiple Sclerosis (MS)
[12–14].
MS is a debilitating neurological disorder characterized by inﬂam-
matory demyelination and axonal/neuronal degeneration, which vari-
ably progresses towards permanent disability [15]. Epidemiological
studies have carefully assessed the BMI as risk factor for MS
[12,13,16–20] and many studies have supported the concept of long-term effects of the BMI on the disease, as obesity or high body mass in
childhood or adolescence will induce disease onset many years later
[12,13,19,20]. Finally, recent studies have highlighted a relationship be-
tween BMI and disease severity [21–25] and to some extent, progres-
sion [26,27], thereby further supporting the need to investigate the
molecular mechanisms responsible for these long-term effects.
Increased lipid synthesis in multiple tissues, including adipose tis-
sue, liver, skeletal muscle and plasma has been associated with high
BMI [28–31]. This is of high interest as lipids are increasingly recognized
as important signalingmolecules regulating a multitude of cellular pro-
cesses, includingproliferation,metabolismandmigration [32].Most rel-
evant to MS is the role of sphingolipids [33] and more speciﬁcally
ceramides, whose altered levels have been reported both in the brains
[34,35], cerebrospinal ﬂuid [36] and plasma [37] of MS patients.
Ceramides are gaining substantial interest as biomarkers for a wide va-
riety of metabolic, cardiovascular and neurological disorders [38,39]
however their precise mechanism of action is not fully understood
and has often been described as cell-speciﬁc [40]. In this study we de-
tected intriguing parallels between elevated plasma levels of ceramide
species, hypermethylation of anti-proliferative genes in monocytes, in-
creased monocytic counts and worsened disease course in MS patients
with high BMI compared to thosewithnormal BMI. Given the strong ep-
idemiological data on the long-term effects of BMI, we further hypothe-
sized that ceramides act as nuclear signaling lipids and epigenomic
modulators with the ability to impact DNA methylation and affect spe-
ciﬁc cellular functions, such as monocyte proliferation.
2. Materials and methods
2.1. Human studies
2.1.1. Primary cohort
All subjects were recruited at the Corinne Goldsmith Dickinson Cen-
ter for Multiple Sclerosis at Mount Sinai. The protocol was approved by
Mount Sinai's Institutional Review Board and all subjects providedwrit-
ten informed consent. Subjects were enrolled from February 2014
through December 2015. Eligible subjects aged 18–60 met criteria for
Relapsing Remitting MS [41] or Clinically Isolated Syndrome along
with a brainMRI consistentwithMS as determined by the treating phy-
sician, and were treatment-naïve with respect to MS disease-modifying
therapy. Exclusion criteria included the diagnosis of another autoim-
munedisease, treatmentwith immunosuppressants, diagnosis of diabe-
tes, recent high dose corticosteroids (b30 days), or recent antibiotics
(b90 days). Details of each subject's demographic and clinical history
and weight were recorded (See Table S1). Expanded Disability Status
Scale (EDSS) [42]was performed by a study co-investigator or in certain
cases abstracted from a recent clinical visit.
Follow up clinical information was obtained through review of the
medical records of all subjects in the spring of 2017. The most recent
clinical visit was chosen as the follow up time point and EDSS was ab-
stracted from this visit. All chart notes from the time of enrollment to
the follow up time point were reviewed to assess for disease activity,
which was deﬁned as any new clinical MS relapse or MRI activity. An
MS relapse was deﬁned as the appearance of a new neurological symp-
tom lasting N24 h in the absence of fever or infection [41] andwas deter-
mined by the treating physician (all MS specialists) for clinical care
purposes independently from the study. MRI activity was deﬁned as
the appearance of a new T2 lesion or new gadolinium-enhancing lesion
on clinical MRI scan, again determined by the treating MS expert inde-
pendently from the study. The frequency of disease activity in normal
and high BMI groups was analyzed using chi-squared test on GraphPad
Prism v7.0. The distribution of therapies in the two groups was also
evaluated using chi-squared test on GraphPad Prism v7.0. Evaluation
of associations between BMI at baseline and EDSS changes from
follow-up to baseline were assessed by ordinal logistic regression on
R. Multivariate analysis was conducted for BMI, age, gender, and race
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dependent association between BMI and EDSS change and corrected
for the other variables. P values b.05 were considered signiﬁcant.
2.1.2. Validation cohort for monocyte counts and brain volume
The validation cohort was obtained from a prospectively-acquired
natural history cohort collected underNIH protocol 09-I-0032: Compre-
hensive multimodal analysis of neuroimmunological diseases of the
CNS (clinicaltrials.gov identiﬁer: NCT00794352). All patients signed
the informed consent and the study was approved by NIH Institutional
Review Board (CNS IRB). All patients were assigned alphanumeric
codes and the personnel generating immunophenotyping or volumetric
MRI data were blinded to the diagnostic conclusion, clinical data or BMI
status. Only treatment-naïve subjects fulﬁlling MS diagnostic criteria
[41] and classiﬁed as RRMS by treating clinician were included (See
Table S2 for demographic and clinical information).
2.1.3. Healthy control cohort for monocyte counts and brain volume
Healthy subjects were prospectively recruited between June 2013
and May 2017 as part of a Natural History protocol “Comprehensive
Multimodal Analysis of Neuroimmunological Diseases of the Central
Nervous System” (ClinicalTrials.gov identiﬁer: NCT00794352) at the
National Institutes of Health. The inclusion criteria were age 18 years
or older and vital signs within normal range at the time of screening
visit. The exclusion criteria included systemic disorder or central ner-
vous system disease of any kind, history of alcohol or substance abuse,
MRI contraindications and history of auditory disorder (See Table S3
for demographic information).
2.1.4. Healthy control cohort for lipidomic analysis
Forty plasma samples for lipidomic analysis of healthy controls (see
Table S4 for demographic information). were purchased from BioIVT.
They included 20 samples from healthy controls with normal BMI (10
males and 10 females with a BMI range of 21–24) and 20 from high
BMI subjects (10 males and 10 females with a BMI range of 26–40).
2.1.5. Immunophenotyping
For the primary RRMS cohort, samples were analyzed blinded. Fresh
whole bloodwas stained in FACS staining buffer formonocytes (CD45+-
CD3−CD14+ cells), CD8 T cells (CD45+CD3+CD8+ cells), and CD4 T
cells (CD45+CD3+CD4+ cells) and CD4 T cell subsets, naïve/Th1 (CD3+-
CD4+CCR4−CCR6− cells), Th17 (CD3+CD4+CCR4+CCR6+ cells), and
Treg (CD3+CD4+CD127−CD25+ cells). To minimize variability, staining
and acquisition were performed on the same day of blood draw within
3 h using the optimized antibody cocktail. Data were acquired on a
Becton Dickinson LSR Fortessa (BD) equipped with ﬁve lasers
(355 nm, 407 nm, 488 nm, 532 nm, and 633 nm wavelengths) with
22 PMT detectors at the Human Immune Monitoring Center at Icahn
School of Medicine. Data were acquired using DIVA 6.1.2 software
(BD). A minimum of 500,000 cells was recorded from corresponding
tubes in order to accurately assess minor cell populations. Compensa-
tion was performed with unstained cells and BD compensation beads
particle sets. FlowJo 9.4 software (Treestar Inc.) was used for post-
acquisition analysis. Debris and doubletswere excluded using light scat-
ter measurements and major cell populations were identiﬁed based on
their forward and side scatter properties. Subsequently, cellswere gated
using CD45 for leukocytes. Each cell populationwas represented as per-
centages of the parent population (i.e. CD4+T cells as % of CD3+ cells,
Treg as % of total CD4+ T cells etc.). Absolute cell counts were calculated
by multiplying the percentage of each cell type compared to the total
population by the white blood cell count.
For the validation RRMS cohort and healthy control cohort, whole
blood immunophenotyping was performed as previously described
[43]. All samples were labeled with a prospectively assigned alpha-
numeric code and personnel performing the studies were blinded to
the diagnosis of the subject. Specimen collection, handling andprocessingwas performed according towritten standard operating pro-
cedures (SOPs). Immunophenotyping of peripheral blood cells was per-
formedon anticoagulated bloodwithin 60min of ex vivo collection after
osmotic lysis of erythrocytes. A minimum of 106 blood cells were
stained according to a previously established protocol [44], which in-
cluded blocking of Fc receptors by 2% intravenous immunoglobulin
(IVIg). Monocytes were identiﬁed based on forward/side scatter and
gating on cell lineage markers (CD45+CD3−CD14+ cells). Cells were
immediately acquired on a BD LSR II with High Throughput Sampler
(HTS) delivery system and analyzed with FACSDiva 6.1 software (all
BD Biosciences). Gating was based on isotype controls. Sample acquisi-
tion, gating and sample exclusion (based on the review of quality of the
staining and of absolute numbers of acquired events to assess reliability
of data) was done on coded samples.
Statistical differences in immune cell counts between normal and
high BMI categories were adjusted for covariates, age and gender, by
One-way MANCOVA on SPSS, followed by pair-wise comparisons be-
tween the two groups with Bonferroni correction to test for statistical
signiﬁcance. P values b.05 were considered signiﬁcant.
2.1.6. Lipidomic Analysis
All lipid standards were purchased from Avanti Polar Lipids, Nu-
Chek Prep, Sigma-Aldrich, Cambridge Isotope Laboratory, Cayman
Chemical Company, Avanti Polar Lipids, or Santa Cruz Biotechnology,
Inc. All solvents are of HPLC or LC/MS grade and were acquired from
Sigma-Aldrich, Fisher Scientiﬁc, or VWR International.
Blinded lipidomic analyses of plasma samples randomized as to the
BMI group, were performed at BERG, LLC. A cocktail of deuterium-
labeled and odd chain phospholipid standards from diverse lipid classes
was added to 25 μl plasma. Standards were chosen so that they repre-
sented each lipid class and were at designated concentrations chosen
to provide the most accurate quantitation and dynamic range for each
lipid species. 4 ml chloroform:methanol (1:1, v/v) was added to each
sample and the lipid extractionwere performed as previously described
[45,46]. Lipid extraction was automated using a customized sequence
on a Hamilton Robotics STARlet system (Hamilton, Reno, NV) to meet
the high-throughput requirements. Lipid extracts were dried under ni-
trogen and reconstituted in 68 μl chloroform:methanol (1:1, v/v). Sam-
ples were ﬂushed with nitrogen and stored at−20 °C. Samples were
diluted 50 times in isopropanol: methanol: acetonitrile: water
(3:3:3:1, by vol.) with 2 mM ammonium acetate in order to optimize
ionization efﬁciency in positive and negative modes. Electrospray
ionization-MSwas performed on a TripleTOF® 5600+ (SCIEX, Framing-
ham, MA), coupled to a customized direct injection loop on an Ekspert
microLC200 system (SCIEX). 50 μl of sample was injected at a ﬂow-
rate of 6 μl/min. Lipids were analyzed using a customized data indepen-
dent analysis strategy on the TripleTOF® 5600+ allowing for MS/MSALL
high resolution and highmass accuracy analysis as previously described
[47]. Quantiﬁcation was performed using an in-house library on
MultiQuant™ software (SCIEX).
Abundance of lipids was quantiﬁed as relative to a lipid standard
with known concentration and ionization efﬁciency. Lipid standards
represented each lipid class so that abundance of lipids within one
class could be compared. Data was ﬁltered and normalized prior to
statistical analysis. Lipids that had missing values in over 50% samples
because they were below the detection limit were excluded. For re-
maining lipids,missing valueswere imputed by sampling a randomuni-
formdistribution ranging from the lowest value detected to one half the
minimum value detected. Lipids were normalized using a variance sta-
bilization procedure to reduce the effect of lipid abundance on sample
variation for each species per lipid class and this was followed by me-
dian centering and log transformation. Because the MS patients and
healthy control samples were obtained at distinct time points, they
were run in separate batches and therefore independently analyzed
for intra-group differences between low and high BMI. To determine
statistically signiﬁcant differences in the abundance of lipids between
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t-tests with 5% FDR correction on Graphpad Prism v7.0 and q values
less than p b .05 were considered signiﬁcant.
The relationship between differentially abundant ceramides (only
18:1 backbone) and brain volume was analyzed by Pearson's correla-
tion. Only patients who had lipidomic and MRI information were in-
cluded in the analysis and p values b.05 were considered signiﬁcant.
Graphpad Prism v7.0 was used to perform the statistical analysis and
create the heat map.2.1.7. DNA methylation analysis
CD14 cells were positively isolated using magnetic beads (Miltenyi
Biotec) and DNA was extracted with QIAamp DNA Blood Mini Kit
(Qiagen). 500 ng of genomic DNA from each sample were bisulﬁte-
treated with Methylamp One-Step DNA Modiﬁcation Kit (EpiGentek)
and methylation levels were measured at ~450,000 CpG sites by using
the Illumina 450 K Array at the New York Genome Center in two differ-
ent batches, which were randomized and blinded to the personnel run-
ning the samples. Methylation values for CpG sites were measured as
beta values, or the ratio of signal intensity between the methylated
probe and the sum of intensities of both methylated and unmethylated
probes, and as M values, or the log2 ratio of the signal intensity of the
methylated probe versus that of the unmethylated one. Because beta
values have more intuitive value for biological interpretation, while M
values are more valid for obtaining statistical signiﬁcance [48], beta
value differences were used to methylation difference values and M
values were used to determine statistical signiﬁcance. Probes with a de-
tection p value of N0.01 and bead count b3 in N5% of the samples were
ﬁltered out. Non-CG probes, those close to SNPs (as deﬁned by Zhou
et al. [49]) or aligned to multiple locations (as deﬁned by Nordlund
et al. [50]), or on sex chromosomes, were removed. Beta values and M
values were normalized with BMIQ v1.6 to correct for Type-I and
Type-II probe bias. Batch effects were removed by using the combat al-
gorithm implemented in the ChAMP package [51]. PCA analysis of the
normalized data did not reveal any outliers in the samples. As we
have previously described [52,53], our analysis was focused on genomic
regions rather than individual CpG sites as regulatory DNA modiﬁca-
tions generally involve multiple consecutive CpGs. To identify differen-
tially methylated regions between overweight/obese MS patients (BMI
≥ 25) and normal BMIMS patients (BMI b 25), we utilized LIMMA pack-
age [54] and used a multilinear regression model, which identiﬁed sig-
niﬁcant correlations (p b .05) between M values at each individual
CpG site and BMI (i.e. partial regression) after controlling for age, sex,
race, EDSS, disease duration, and batch effect. We then used a 1 kb slid-
ing window as implemented in the package DMRcate [55] to deﬁne ge-
nomic regions with closely located CpG sites that were either
differentially methylated or not. Overlapping regions were removed.
Based on these regions that were spanning thewhole genome,we com-
bined eachCpG-speciﬁc p value fromour linear regressionmodelwithin
a single regionwith Stouffer'smethod [56]. Thiswas followed by 1% FDR
correction for multiple hypothesis testing. Differentially methylated re-
gions (DMRs) were deﬁned as regions with an FDR-adjusted combined
p value of b0.01. Data analysiswas performed in R Studio byutilizing the
R packages ChAMP [51] for data preprocessing and normalization,
LIMMA for linear regression [54], and DMRCATE for the 1 kb sliding
window function and the p value combinationwith the Stouffermethod
[55] and q value [57] for FDR correction.
Pathway enrichment analysis was performed on hypermethylated
CpGs using the Kyoto Encylopedia of Genes and Genomes (KEGG) data-
base on Enrichr [58,59]. Genes containing individual CpGs, which corre-
lated with BMI (p b .05) after adjusting for clinical and demographic
variables, were used to broaden the gene base. Enrichment scores for
KEGG terms were calculated as the –log (adjusted p value). Genes
with the largest methylation differences were determined by averaging
the beta value differences of each CpG within the DMR.2.1.8. MRI Measurements
In a primary cohort of MS patients, brain volumetric analysis was
conducted on available T1-weighted sequences (TE = 9.5–24.0 ms, TR
= 359–612 ms) and normalized brain volume (NBV) was measured
on baseline T1-weighted images using SIENAX [60]. Personnel were
blinded to the BMI status of the patients. Due to the nature of the
data, acquired for clinical purposes, further segmentation in gray and
white matter tissues was not performed. Quantiﬁcation of T1-
weighted lesion load was also conducted on available T1-weighted se-
quences (TE = 9.5–24.0 ms, TR = 359–612 ms) at baseline and the
two-year follow-up. T1 lesions were identiﬁed and outlined, for each
patient, using a semi-automated technique based on user-supervised
local thresholding (Jim version 7; Xinapse Systems, http://www.
xinapse.com) at each time point. Changes in lesion loadwere computed
as the difference between lesion volume measured on follow-up scan
and baseline lesion volume. Changes in NBV could not be calculated
since the available sequences from baseline and follow-up were not
comparable.
In a validation cohort of MS patients and healthy controls, the vol-
ume of brain structures were calculated using LesionTOADS [61] tissue
segmentation with T1- and T2-weighted MRI images. Total brain vol-
umewas deﬁned as the sum of white and gray matter and brain paren-
chymal fraction was calculated as the total brain percentage of the sum
of total brain and total CSF volume.
Correlations between monocyte counts and brain volume were per-
formed using linear regression. Evaluation of changes in T1 lesion vol-
ume were performed using chi-squared test. All analyses were
performed on Graphpad Prism v7.0 and p values b.05 were considered
signiﬁcant.
2.2. Cell culture experiments
2.2.1. Monocytic cell line culture
THP1 cells (TIB-202, ATCC) were derived from a one-year old male
infant with acute monocytic leukemia. Cells were cultured using com-
plete RPMI (RPMI 1640 Medium (Sigma), 10% FBS, 1% Penicillin-
Streptomycin, 1% L-Glutamine, 1% HEPES, 1% Non-essential amino
acids, 1% MEM Sodium Pyruvate, 0.05 mM 2-Mercaptoethanol). For vi-
sualization of NBD-labeled Ceramide C16, cells were treated with 5
uM NBD-Ceramide C16 for 24 h. To assess the effects of a single cer-
amide, cells were treated with 100 nM Ceramide C16:0 (Avanti Polar
Lipids) for 1, 12, or 24 h, or untreated, and harvested simultaneously.
Cells were treated with a cocktail of ceramides at different concentra-
tions – 1. Low: 100 nM Ceramide C16:0 (Avanti Polar Lipids), 300 nM
Ceramide C22:0 (Avanti Polar Lipids), 1 uM Ceramide C24:1 (Cayman
Chemicals) and 2. High: 120 nM Ceramide C16:0 (Avanti Polar Lipids),
420 nM Ceramide C22:0 (Avanti Polar Lipids), 1.3 uM Ceramide C24:1
(Cayman Chemicals), with or without 1 uM 5-aza-2′-deoxycytidine
(Sigma) for 1 h followed by a 23 h wash period or for 24 h. For visuali-
zation of NBD-labeled Ceramide C16, cells were treatedwith 5 uMNBD-
Ceramide C16 for 24 h.
2.2.2. Immunostaining
THP1 cells were grown on LabTekII chamber slides during the cer-
amide treatment and then ﬁxed with 4% PFA for 15 min. DNA methyla-
tion levels were assessed by anti-5-methylcytosine staining as
previously described [62]. Brieﬂy, cells were permeabilized with 0.4%
Triton X-100 for 15 min followed by denaturation with 2 N HCl for
15 min and neutralization with 100 mM TrisHCl for 10 min. Cells were
blocked with 10% goat serum, 3% bovine serum albumin (BSA) in PBS
containing 0.1% Triton X-100 for 1 h. Cells were incubated in anti-5-
methylCytosine (Eurogentec, 1:500) and anti-Ki67 (Abcam, 1:1000) to
measure proliferation at 4C overnight. Cells were stained with anti-
mouse AlexaFluor 546 (Invitrogen, 1:500) and anti-rabbit AlexaFluor
488 (Invitrogen, 1:500) the next day for 2 h followed by washing and
mounting with Fluoromount-G containing DAPI. For visualization of
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Triton X-100 in PGBA (0.1 M phosphate buffer, 0.1% gelatin, 1% BSA,
0.002% sodium azide) for 1 h followed by overnight incubation with
anti-4-ﬂuoro-7-nitrobenzofurazan (NBD) (BioRad, 1:100) at 4C. Cells
were stained with anti-rabbit AlexaFluor 488 (Invitrogen, 1:500) the
next day for 1 h and mounted with Fluoromount-G containing DAPI.
2.2.3. Imaging
Images were acquired at 20× on the Zeiss LSM800 and 3 images per
well were taken. For each experiment, 3–4 wells were used per condi-
tion, and a total of 3 independent experiments were performed. Mean
intensity was analyzed on ImageJ. Brieﬂy, DAPI+ nuclei were used to
create Regions of Interest (ROIs) using the Analyze Particles function
and added to the ROI manager. Mean gray values of each ROI were cal-
culated for 5-methylcytosine and Ki67 stainings. An arbitrary threshold
for each staining was set to determine 5-methylcytosine and Ki67 pos-
itive cells that was validated bymanual counting. Percentage of positive
cells over total cells was calculated for each image. The percentages for
all images within onewell were averaged followed by averaging of per-
centages in wells for each experiment. For statistical analysis, Student's
t-testwas performed between two groups, andDunnett'smultiple com-
parisons test was used among three groups and was calculated on
Graphpad Prism v7.0. P values b.05 were considered signiﬁcant. 3D re-
construction of cells treated with NBD-ceramide C16 was performed
on Imaris.
2.2.4. MTT
The MTT assay was performed as previously described [63]. THP1
cells were treated with different doses of 5-aza-2′-deoxycytidine (0,
0.5, 1, 2, 5 uM). After 24 h of treatment, 5 mg/ml MTT was added to
the cell media to a ﬁnal concentration of 0.05 mg/ml and allowed to in-
cubate for 3 h to allowMTT reduction. The formazan precipitate formed
by viable cells was solubilized in DMSO, and read spectrophotometri-
cally at 540 nmwith background subtraction at 655 nm.
2.2.5. Sequenom mass array EpiTyper
Genomic DNA was isolated using the DNeasy Blood and Tissue Kit
(Qiagen). DNA purity was assessed by measuring the A260/A280 ratio
using NanoDrop. 200 ng genomic DNA was sodium bisulﬁte–treated
using the Methylamp One-step Modiﬁcation Kit (Epigentek). Primers
were designed using EpiDesigner software: NRXN1 intron forward:
GTGTTATTGAGGAGTTAATGGTTGA, NRXN1 intron reverse: ATTTCCCCT
CTATATTTAACAATCACA, FZD7 promoter forward: TTATTGAGAAGTGA
TTTGGAAGTGA, FZD7 promoter reverse: ACCTCACAAAAATCTAAACAA
ACCA, TP63 promoter forward: GTTTTAAATTGTTAATAATAAGTGTG
GTT, TP63 promoter reverse: AAAATTTAAACACTTCTCTCCTTCA, TP63
exon forward: TTTTTTTGTAAATATGTATGAAGGAGAGA, TP63 exon re-
verse: AAAAAATTATATCACATTCAAACTCACC. Forward primers were
designed with a 10-mer tag (AGGAAGAGAG) and reverse primers de-
signed with a T7-promoter tag (CAGTAATACGACTCACTATAGGGAGA
AGGCT), as per the manufacturer's guidelines. PCR products were then
processed as previously described to determine methylation levels.
CpGs overlapping silent peaks, outside themass spectrometry analytical
window (low or highmass), or lacking sufﬁcient coverage (methylation
level determined for b90% of samples) were ﬁltered out before subse-
quent analysis. Statistical analysis for the overall region (taking all indi-
vidual CpGs into account) was performed by Two-way ANOVA on
Graphpad Prism v7.0 and p values b.05 were considered signiﬁcant.
2.2.6. Quantitative real time PCR
RNAwas extracted from THP1 cells using Trizol (Invitrogen) extrac-
tion and isopropanol precipitation. RNA samples were resuspended in
water and further puriﬁed with RNeasy columns with on-column
DNase treatment (Qiagen). RNA purity was assessed by measuring the
A260/A280 ratio using NanoDrop. For qRT-PCR, RNA was reverse-
transcribed with qScript cDNA Supermix (Quanta) and performedusing PerfeCTa SYBR Green FastMix, ROX (Quanta) at the Epigenetics
Core at the Advanced Science Research Center at CUNY. Primer se-
quences are as follows: NRXN1 forward: TAAGTGGCCTCCTAATGACCG,
NRXN1 reverse: TCGCACCAATACGGCTTCTTT, FZD7 forward: GTGCCA
ACGGCCTGATGTA. FZD7 reverse: AGGTGAGAACGGTAAAGAGCG TP63
forward: TCCTCAGGGAGCTGTTATCC, TP63 reverse: ATTCACGGCTC
AGCTCATGG, RPLP0 forward: GCGACCTGGAAGTCCAAC, RPLP0 reverse:
GTCTGCTCCCACAATGAAAC. 3 technical triplicates per biological repli-
cate, 3 biological replicates per experiment, and 3 independent experi-
ments were performed. After normalization to the housekeeping gene,
RPLP0, CT values of technical triplicates were averaged for each biologi-
cal replicate, followed by averaging of biological replicates for each in-
dependent experiment. Values were normalized to the average value
of control conditions (i.e. “Untreated” or “Low”). Statistical analysis
was performed onGraphpad Prism v7.0: Student's t-test was performed
between two groups, andDunnett'smultiple comparisons testwas used
among three groups. P values b.05 were considered signiﬁcant.
2.2.7. Generation of NBD-Ceramide C16
NBD Sphingosine was purchased from Avanti® Polar Lipids, Inc.
(Cat. Nr. 810205). All other reagents and solvents were purchased
from commercial sources (Sigma-Aldrich, Fisher Scientiﬁc, etc.) and
were used without further puriﬁcation. Reaction progress was moni-
tored by LC-MS analysis. HPLC (1260 inﬁnity II, Agilent) was used for
puriﬁcation of NBD-Ceramide C16:0.
Stock solutions of palmitic acid (0·05 M), TBTU (0·05 M), DIPEA
(0·05 M), and NBD sphingosine (0·01 M) in EtOAc were prepared.
Palmitic acid (3·00 ul, 0·15 umol), TBTU (3·00 ul, 0·15 umol), and
DIPEA (6·00 ul, 0·30 umol) were added to a microcentrifuge tube
(1·5 ml) and incubated for 1 h under mild orbital shaking. NBD sphin-
gosine (10·0 ul, 0·10 umol) was added and the reaction mixture was
incubated for 16 h under mild orbital shaking (starting material
completely consumed by LC-MS). MeOH was added and the reaction
mixture was transferred into a glass vial. The crude mixture was puri-
ﬁed by preparative HPLC (H2O & 1% Formic Acid (10%) in CH3CN to
CH3CN) to yield NBD-Ceramide C16:0 as a yellow solid with approxi-
mately 80% recovery rate (yield estimate used for concentration calcula-
tions: 57·3 μg, 0·08 umol). HRMS (EI+):m/z calcd. For [C40H70N5O6] +:
716·5321, found: 716·5326 ([M + H]+).
2.3. Animal experiments
2.3.1. Animals
All experiments were performed according to IACUC-approved pro-
tocols and mice were maintained in a temperature- and humidity-
controlled facility on a 12-h light-dark cycle with food and water ad
libitum. Female C57/bl6 mice (The Jackson Laboratory) were fed a
low-fat diet (2914, Envigo) or high fat diet (TD.96132, Envigo) starting
at 3–4 weeks of age. Experimental autoimmune encephalitis (EAE) was
induced after 5 weeks of diet as previously described [64]. Brieﬂy, mice
were injected subcutaneously with 200 μg of MOG35–55 thoroughly
emulsiﬁed in Complete Freund's Adjuvant (CFA) with 500 μgMycobac-
terium tuberculosis dissolved in 200 μl of a solution consisting of equal
amounts of 1.5mg/mlMOG peptide, 2.5 mg/mlMycobacterium tubercu-
losis and 50% CFA. 500 ng of pertussis toxin dissolved in 200 μl of PBS
were administered intraperitoneally at the time of the MOG35–55 injec-
tion and 2 days thereafter. Disease progression was monitored daily
using a standard EAE scoring system (modiﬁed from the Hooke Lab rec-
ommendations) as following: 0= no visible symptoms, 1= ﬂaccid tail,
1·5= limp tail and hind leg inhibition, 2= limp tail andweakhind legs,
2·5= limp tail and dragging of hind legs, 2·75= limp tail and paralysis
of one hindlimb, 3 = limp tail and complete hindlimb paralysis, 3·5 =
limp tail, complete hindlimb paralysis, and weakness of forelimbs, 4 =
quadriplegia, and 5 = death.
For analysis of inﬁltrating monocytes in the CNS, Cx3cr1-Gfp mice
(B6.129P-Cx3cr1tm1Litt/J) and Ccr2-Rfp mice (B6.129(Cg)-Ccr2tm2.1Ifc/J)
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Cx3cr1Gfp/+;Ccr2Rfp/+ mice. Heterozygous female mice were used for
the experiments and fed a low-fat diet (2914, Envigo) or high fat diet
(TD.96132, Envigo) starting at 4 weeks of age for a period of 5 weeks.2.3.2. Analysis of disease course
Changes inweightwere calculated after 5weeks of diet as ameasure
of weight gain and were assessed by Student's t-test in low fat diet and
high fat diet groups. Blood glucose test strips (Contour) were used to
measure blood glucose levels as an indication of pre-diabetes and differ-
ences were assessed by Student's t-test. EAE scores were recorded to
evaluate disease course. The difference in weight from baseline weight
(weight at immunization) was calculated for each time point through-
out disease course. Differences in weight change for individual time
points were assessed by Sidak's multiple comparisons test. Differences
in clinical severity on individual time points were assessed by Mann-
Whitney U test. Area under the curve and maximum EAE score were
also assessed for each mouse and compared in low fat diet and high
fat diet fed mice by Mann-Whitney U test. Calculations and statistical
analysis were performed on Graphpad Prism v7.0 and p values b.05
were considered signiﬁcant.2.3.3. Immunostaining
Micewere sacriﬁced at the peak of EAE for histological analysis. Mice
were anaesthetized and perfusedwith 4% (w/v) paraformaldehyde. Spi-
nal cordswere removed, post-ﬁxed, and cryopreserved in 30% (w/v) su-
crose, embedded in OCT and sectioned coronally (12 μm). Sectionswere
blocked with 10% goat serum, and 0.1% Triton X-100 in PGBA (0.1 M
phosphate buffer, 0.1% gelatin, 1% BSA, 0.002% sodium azide) for 1 h
followed by overnight incubation with primary antibodies – NFH
(Millipore, 1:400), CD45 (BD Biosciences, 1:100), Iba1 (Wako, 1:500),
and 5-methylCytosine (Zymo Research, 1:100) at 4C overnight. For 5-
methylCytosine staining, antigen retrieval was performed using sodium
citrate buffer at 95C for 15 min prior to blocking. Sections were washed
and incubated with secondary antibodies, anti-mouse AlexaFluor 546
(Invitrogen, 1:500), anti-rabbit AlexaFluor 488 (Invitrogen, 1:500) and
anti-rat AlexaFluor 647 (Invitrogen, 1:500), followed by counterstaining
with DAPI (1:20,000) and mounting with Immunomount (Electron Mi-
croscopy Sciences). Fluoromyelin Green (Invitrogen, 1:300) was ap-
plied to sections for 20 min at room temperature after incubation with
primary antibodies.2.3.4. Imaging
To assess demyelination, axonal loss, and monocyte inﬁltration, im-
ages were acquired at 20× on the Zeiss LSM800. At least three images
per section were acquired in two sections per animal and at least
three animals were analyzed for each condition. Images were taken as
a Z-stack and the maximum projection was acquired using the Zeiss
Zen software. Areas were calculated on ImageJ. Fluoromyelin and NFH
+ areas were delineated manually. To calculate CD45+ area, images
were thresholded and the area calculated using the “analyze particles”
function. Regions of interest (ROIs) were deﬁned as CD45+ areas, and
Iba1+ area was calculated within CD45+ areas using a threshold. Total
Iba1+CD45+ area for each image was calculated as the sum of Iba1+
area for all CD45+ areas or ROIs in each image. ROIs were limited to
the lesion area. To assess DNAmethylation levels, imageswere acquired
at 63× on the Zeiss LSM800. 3 images per sectionwere taken and 2 sec-
tions per animal and 3 animals per condition were assessed. Intensity
was deﬁned as mean gray value and calculated on Image J. 5 represen-
tative nuclei of Iba1+ cells were selected manually in each image and
5mc and DAPI intensity were calculated. For statistical analysis,
Student's t-test was performed on Graphpad Prism v7.0 and p values
b.05 were considered signiﬁcant.2.3.5. Flow cytometry
Brains and spinal cords were removed and homogenized. Mononu-
clear cellswere separatedwith a 30%/70% Percoll (GEHealthcare) gradi-
ent as previously reported [65]. Single-cell suspensions were analyzed
on a FACSAria II Cell Sorter (BD) equipped with ﬁve lasers (355 nm,
407 nm, 488 nm, 532 nm, and 633 nm wavelengths) running DIVA
6.1.2 software (BD). Data were analyzed with FlowJo v10.0.7 software
(Tree Star). Brieﬂy, mononuclear cells were identiﬁed by size (forward
and side scatter) and doublets excluded. Inﬁltrating monocytes were
identiﬁed as CCR2-RFP+ and microglia as CX3CR1-GFP+. Percentages
of CCR2-RFP+ and CX3CR1-GFP+ cells of total singlets were calculated
for 5 mice per group. For statistical analysis, Student's t-test was per-
formed on Graphpad Prism v7.0 and p values b.05 were considered
signiﬁcant.2.4. Quantiﬁcation and statistical analysis
Analysis of immunophenotyping was performed on SPSS. DNA
methylation analysis and ordinal logistic regression of BMI and
EDSS change were analyzed using R. All other statistical analyses
were done using GraphPad Prism. For all graphs, error bars are
mean ± SEM. All statistical details for each graph can be found in
the ﬁgure legends.2.5. Data and software availability
Sequencing data deposited in NCBI's Gene Expression Omnibus
Series accession number GSE103929.3. Results
3.1. Immune proﬁling reveals increased monocytic counts in MS patients
with high BMI
The discovery cohort consisted of ﬁfty-four patients who had been
recently diagnosed with Relapsing-Remitting MS (RRMS) and had
been recruited to participate in the study prior to the initiation of
disease-modifying therapy (“therapy-naïve”). Patients were classiﬁed
by BMI as normal (average BMI=21·8±1·9, n=27) or high (average
BMI = 30·2 ± 5·0, n = 27). At baseline, the clinical disability score, as
deﬁned by the Kurtzke Expanded Disability Status Scale (EDSS), did not
differ by BMI (MSwith normal BMI:median±SD=2·0±1.1;MSwith
high BMI:median± SD=1·0± 1·0), as patients were recruited at the
early stages of disease (Table S1).
Since MS is an immune-mediated demyelinating disease, we sought
to deﬁne whether the peripheral immune proﬁles differed in patients
with different BMIs. Immunophenotypingwas conductedusingﬂow cy-
tometry for the detection of surfacemarkers. The total number of circu-
lating CD4 T cells and related subsets, CD8 T cells and monocytes
(CD14+) were calculated (Fig. S1). CD8 T cells and total CD4 T cell
counts were not signiﬁcantly different among MS patients with differ-
ing BMI, nor were CD4 naïve/Th1 (CCR4− and CCR6−), Th17 (CCR4+
and CCR6+) and Treg (CD25hi and CD127−) subsets (Fig. 1A). However,
the number of CD14+ monocytes was signiﬁcantly higher in MS pa-
tients within the high BMI group, after adjusting for age and sex statis-
tically, a ﬁnding that was validated in a second independent validation
cohort of 91 therapy-naïve RRMS patients (normal BMI average =
21·4 ± 1·9, n = 42; high BMI average = 29·6 ± 4·4, n = 51) and
was not detected in 50 healthy controls (normal BMI average = 21·5
± 2·3, n = 13; high BMI average = 30·2 ± 4·5, n = 37) (Fig. 1B).
This suggested that in out cohorts, the number of circulatingmonocytes
was uniquely affected by the interplay between high BMI and MS dis-
ease state.
Fig. 1. Immune proﬁling reveals a BMI-dependent increase in blood monocyte counts in MS patients but not healthy individuals. Immune cell populations from fresh whole blood were
quantiﬁed using ﬂowcytometry. (a) Differences in T cell counts due to BMIwere assessed in a primary cohort ofMS patients (n=52). (b)Differences inmonocyte counts due to BMIwere
assessed in a primary cohort of MS patients (n= 52), a validation cohort ofMS patients (n=91), and a cohort of healthy individuals (n=50). One-wayMANCOVAwas used to adjust for
age and sex, followed by pair-wise comparisons with Bonferroni correction to determine statistically signiﬁcant differences in the two BMI groups (normal BMI=white dots, high BMI=
gray dots) (*p b .05).
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MS patients with high BMI
Because differences in BMI have been associated with lipid changes
in several tissues [28,29,31], we asked whether MS patients with nor-
mal or high BMI also differed in circulating lipids. Plasma samples
were analyzed using an MS/MSALL platform which identiﬁed over
2000 lipids (within 13 lipid classes), and the relative abundance for
each lipid species was calculated in reference to reliable standards
with known abundance and ionization efﬁciency for each lipid class.
Lipids were excluded if values were below the detection limit in over
50% of samples, yielding 1030 lipid species that were considered suit-
able for further analysis. Differentially abundant lipids were identiﬁed
bymultiple t-tests with 5% FDR correction for each lipid class, revealing
sphingolipids and neutral lipids as more abundant in the high BMI
group than in normal BMIMS patients (Fig. S2A). The largest percentage
difference in abundance was detected for the ceramides (38%), a sub-
class of sphingolipids, followed by triglycerides (30%) and diacylglycer-
ols (18%) within the neutral lipids class (Fig. 2A). To further determine
whether the ceramide abundance in the high BMI group of MS patients
was speciﬁc to the disease state, or simply reﬂected the effect of high
body mass, we conducted a similar analysis on a cohort of 40 plasma
samples from healthy controls with either a normal (average =
22·6.5 ± 1·1, n = 20) or high BMI (average = 29·4 ± 3·4, n = 20)
(Fig. 2B, Fig. S2B). Interestingly, the ceramide species with differential
abundance in the plasma of MS patients with high BMI, were not simi-
larly elevated in healthy individuals with high BMI, thereby suggesting
that, at least within the limited size of the cohort included in our
study, the speciﬁc ceramide species detected in patients were the likely
result of the process of myelin destruction, characteristic of the diseasestate (Fig. 2C). This concept was further supported by an inverse corre-
lation between speciﬁc ceramides and brain volume (Fig. S3). Overall
these data suggested that the increased ceramide species detected in
MS patients with high BMI, were the likely result of the combined de
novo synthesis of ceramides from dietary fats and their recycling from
myelin, damaged by the disease process.
3.3. Ceramide treatment increases DNAmethylation and enhances prolifer-
ation in cultured monocytes
To begin deﬁning a potential relationship between elevated cer-
amide levels and increased monocyte counts in high BMI MS patients,
we used an in vitro approach and treated monocytic cell lines with dif-
ferent ceramides.
To deﬁne whether plasma ceramides could be uptaken by
monocytes,we exposed cultured cells toﬂuorescently-labeled ceramide
C16 (i.e. synthetically conjugated to the small ﬂuorophore
nitrobenzoxadiazole to formNBD-ceramide C16) for 24 h, and collected
several confocal images. A 3D reconstruction of those images revealed
both nuclear and cytoplasmic localization of the labeled ceramide
within monocytic cells (Fig. 3A). Next, we performed a time course of
ceramide C16 on monocytes, which revealed increased proliferation
after 12 or 24 h of treatment, compared to baseline (Fig. 3B). Intrigu-
ingly, in the ceramide C16 treated cells we also detected increased
DNAmethylationwhich occurred as early as 1 h after exposure and pre-
ceded the effects on proliferation. This ﬁnding was of great interest as
previous studies had reported an effect of fatty acids on DNA methyla-
tion in monocytes [66–70]. To further validate these results, we con-
ducted a similar experiment but exposed the cells to the cocktail of
ceramide species which we identiﬁed as differentially abundant in the
Fig. 2. Lipidomic proﬁling reveals increased abundance of ceramide species in MS patients with high BMI, but not in healthy individuals. Unbiased lipidomic analysis was performed on
plasma samples from MS patients (n = 48) and healthy individuals (n= 40) using an MS/MSALL platform. Lipids that differed in abundance due to BMI were assessed using multiple
t-tests with 5% FDR correction, q b 0.05 were considered signiﬁcant (*q b 0.05, **q b 0.01). (a) Pie chart representation of numbers and percentage of lipids in MS patients by lipid family
and class. Red= increased abundance, blue= decreased abundance, white = no change in patients with high BMI. (b) Relative abundance of ceramide species with 18:1 backbone that
were signiﬁcantly different in abundance inMS patients with high BMI (gray dots) compared to those with normal BMI (white). (c) Themost highly signiﬁcantly abundant ceramide spe-
cies in MS patients were not statistically different in healthy individuals with high BMI (gray dots) compared to those with normal BMI (white).
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and C24:1). Each cocktail was prepared based on the physiological cer-
amide concentrations detected in human plasma [37,71,72] and
reﬂected the relative high or low abundance of ceramide species de-
tected in our lipidomic analysis. Monocytes exposed for 24 h to the
cocktail corresponding to the ceramide species levels detected in the
plasma samples fromMS patients with high BMI showed increased pro-
liferation and DNAmethylation compared to cells exposed to the lower
concentrations of ceramides, equivalent to those detected in the normalBMI MS group (Fig. 3C). Importantly, the effect of ceramide on prolifer-
ation was prevented by co-treatment with the DNAmethylation inhib-
itor, 5-aza-2′-deoxycytidine (5-aza) at doses of 5aza that were well
tolerated by the cells (Fig. S4). The effect on proliferation and DNA
methylation was not detected with treatment of shorter duration
(Fig. 3C). Together, these results support a relationship between
ceramide-induced effects on DNAmethylation and increasedmonocyte
counts, as detected in the high-BMIMS patients compared to thosewith
normal BMI.
Fig. 3. Exposure to ceramides results in dose-dependent increase in proliferation and DNA methylation. (a) Cultured monocytes (i.e. THP1 cells) were treated with ﬂuorescently labeled
Ceramide C16 (NBD-Ceramide C16) or untreated for 24 h. 3D reconstruction of the cells was conducted on Imaris to visualize localization of NBD-Ceramide (green). (b) Cultures either
untreated or treated with Ceramide C16 (Cer C16) for 1, 12, or 24 h were ﬁxed at the same time. After immunocytochemistry for Ki67 to detect proliferating cells or5-methylcytosine
as marker for global DNA methylation the percentage of cells relative to the total DAPI+ nuclei was calculated and plotted in the graphs. Statistical differences in the percentage of
Ki67+ cells and percentage of 5mc + cells relative to total DAPI+ nuclei were assessed by Student's t-test. (c) Cultures were treated for 1 (left panels) or 24 (right panels) hours with
concentrations of a mixture of ceramides C16, C22, and C24:1, mimicking those detected in the plasma of MS patients with normal (Low) or high BMI (High) in the absence or
presence of the DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-aza). After ﬁxation, cells were stained for Ki67 (green) as proliferation marker, 5-methylcytosine (5mC, red), as
marker for global DNA methylation and DAPI (blue), to identify nuclei. Confocal images were acquired at 20× magniﬁcation using the Zeiss LSM800 confocal (scale bar = 25um). High
and High+5-aza groups were compared to Low Cer at 24 h using Dunnett's multiple comparisons test (*p b .05, **p b .01) (n= 3 independent biological replicates, each conducted in
triplicate wells and analyzing 3 images/well).
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with high or normal BMI
The previously mentioned epidemiological evidence on the long-
term consequence of high BMI in childhood and adolescence on the
risk to develop MS [17,19,20], the recognition of the overall importance
of epigenetic changes as the interface between genetic predisposition
and environmental variables and the documented responsiveness of
monocytic DNA methylation to lipids [66–70], collectively informed
our decision to conduct an unbiased genome-wide analysis of DNA
methylation in monocytes sorted from MS patients differing by BMI.We used the Illumina 450 K Array, which accounts for approximately
485,000 CpG sites and covers 99% of all RefSeq genes and 98% of gene-
associated CpG islands in the human genome, thereby providing an ex-
tensive and reliable coverage of the gene-rich regions. Individual CpGs
were evaluated using amultilinear regressionmodel to identify the con-
tribution of BMI on DNA methylation changes after controlling for age,
race, sex, EDSS and disease duration. We adopted a sliding window of
1 kb to interrogate the genome [55] and used well-accepted criteria of
analysis [73] to deﬁne genomic regions with similarly regulated CpGs,
which we termed Differentially Methylated Regions (DMRs). The over-
all DNAmethylation effect of each clustered region was then computed
Fig. 4.Genome-wide distribution ofDNAmethylationmarks inmonocytes of highBMIMSpatients. DNAmethylation analysiswas conductedonDNA frommonocytes ofMSpatients using
the InﬁniumHumanMethylation450BeadChip. DNA samples from themonocytes ofMS patientswith highBMI (n=23)were compared to those frompatientswith normal BMI (n=25).
Differentially methylated regions (DMRs) were identiﬁed using a 1 kb sliding window and signiﬁcantly different CpGs were determined by evaluating the combined p values of CpG sites
within each region, using the Stouffer'smethodwith a 1% FDR correction. (a)Methylation values of individual CpGswithinDMRsweremeasured as beta values, or the signal intensity from
themethylated probe in relation to the sumof intensities frombothmethylated and unmethylatedprobes. Beta values of CpGs inMS sampleswith high BMIwere subtracted from those in
with normal BMI and a frequency histogram of the beta value differences was plotted to visualize the frequency of beta value differences in a given range. Positive beta value differences,
indicating DNA hypermethylation in high BMIMS samples, are plotted in red, whereas negative differences, indicating DNA hypomethylation, are in blue. (b) Genomic distribution of the
hypermethylatedDMR in patients with high BMI (black bars), compared to the distribution of all the CpGs in the array (white bar). The relative proportions of CpGs in islands, shores (2 kb
ﬂanking the islands), shelves (2 kb ﬂanking the shores) and sea (regions outside the previous three categories) are indicated. (c) Distribution of the hypermethylated CpGs distributed
within in MS patients with high BMI (black bars) within distinct gene features, compared to the distribution of all the CpGs in the array (white bar). The relative proportion of
differentially methylated CpGs in high BMI MS patients is represented relative to RefSeq gene promoters (2 kb from TSS), 5’UTR, 1st exon, gene bodies, 3’UTR and intergenic regions.
Note that the CpGs hypermethylated in MS patients with high BMI were enriched at promoters and intergenic region and depleted at gene bodies, consistent with a repressive pattern
of DNA methylation. Enrichment deﬁned as statistically signiﬁcantly different from the proportion of total array CpGs in a given location, which was calculated by chi- squared test, *p
b .05, **p b .01. (d) Pathway enrichment analysis was performed on hypermethylated CpGs using the KEGG database on Enrichr. Enrichment score was calculated as the -log (adjusted
p value).
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rection for multiple hypothesis testing. This analysis identiﬁed 160
DMRs as hypermethylated and 18 DMRs as hypomethylated in the
monocytes sorted from the MS patients with high BMI compared to
those with normal BMI (Fig. S5). Therefore, we observed skewing of
monocyte-derived DNA towards hypermethylation and focused on
hypermethylated DMRs for further analysis (Fig. 4A).
When the CpG distribution of the hypermethylated DMRs was com-
pared to the CpG distribution of all tested probes in the Illumina 450 K
array, we detected enrichment in CpG islands and shores (±2 kb from
islands) and concomitant reductions in the shelves (±2 kb from shores)
and open sea (the remainder of genomic regions) (Fig. 4B). Further
evaluation of the DMRs by gene features revealed enrichment of
DMRs at promoters and intergenic regions and depletion at the 5’UTR
and within gene bodies (Fig. 4C). Such a distribution is suggestive of
transcriptional repression. To begin deﬁning the potential functional
relevance of these differences in DNA methylation, we then performed
a pathway enrichment analysis of the hypermethylated genes in the
monocytes of high BMI patients, which revealed cancer-related path-
ways, enriched for genes regulating cell proliferation. Enrichment in
the categories of cell adhesion molecule (CAM) and actin cytoskeleton
were also indicative of biological processes related to cell proliferation
(Fig. 4D).The chromosomal distribution of DMRs visualized by Circos plot did
not reveal any preferential chromosomal distribution (Fig. 5A), how-
ever visualization of the genes with the highest average methylation
using a Manhattan plot (Fig. 5B) identiﬁed genes, whose function had
been linked to negative regulation of cell proliferation. These genes in-
cluded: NRXN1 (Neurexin 1alpha), a membrane protein with the ability
to negatively regulate hematopoiesis [74]; TP63 (Tumor Protein P63), a
member of the p53 family of transcription factors, which negatively reg-
ulates proliferation in an isoform-speciﬁc manner [75]; and FZD7
(Frizzled class receptor 7), a receptor for severalWNT ligands, which reg-
ulates proliferation in a P63-dependent manner [76]. Collectively, these
data identify DNA hypermethylation of genes negatively regulating cell
proliferation as part of the mechanism underlying the higher monocyte
counts detected in high-BMI MS patients.
3.5. Hypermethylation and decreased transcript levels of regulators of pro-
liferation in ceramide-treated monocytes
To functionally relate these ﬁndings to the results of the unbiased
lipidomic analysis, we asked whether treatment of cultured human
monocytic lines with ceramides would induce DNA hypermethylation
at the same genomic locations identiﬁed in the monocytes directly
sorted from the patients' blood. DNA methylation at target genes (i.e.
Fig. 5. Chromosomal distribution and identiﬁcation of genes with most signiﬁcantly hypermethylated regions in MS patients with high BMI identiﬁes negative regulators of cell
proliferation. (a) Circos plot representing the chromosomal distribution of DMRs and CpGs within DMRs. Chromosomal numbers are indicated in the innermost circle. The inner red
and blue circle depict the beta value differences for each CpG within a DMR. The more hypermethylated the CpG (bright red) the farther it is from the center of the circos plot, and the
more hypomethylated the CpG (blue) the closer it is to the center of the plot. Dark red lines in the outer circle denote the genomic location of the DMRs and dark red dots indicate the
mean beta value difference for each DMR. Genes overlapping DMRs are indicated in the outermost circle and genes with the greatest methylation differences are highlighted in red.
(b) Manhattan plot highlighting the overall methylation difference, or mean beta change, for each DMR on each chromosome.
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based approach (i.e. Sequenom EpiTyper), which validated the occur-
rence of statistically signiﬁcant hypermethylation induced by ceramidetreatment at the previously identiﬁed genomic locations (Fig. 6A). The
ceramide-induced hypermethylation was associated with decreased
transcript levels of NRXN1, FZD7 and TP63, compared to untreated
Fig. 6. Exposure to ceramides results in increased DNAmethylation and reduced transcription of negative regulators of cell proliferation. (a) Cultured human monocytes (i.e. THP1 cells)
were either untreated (blue) or treated with Ceramide C16 (red) for 24 h. DNA was harvested and processed for Sequenom Mass Array EpiTyper, in order to quantify differential
methylation of CpGs (Y axis) at the indicated genomic locations (X axis). The gene name is shown on top of each graph. (b) samples from the same cells described in (a) were used for
RNA isolation and quantiﬁcation of the corresponding gene transcripts by using real time-PCR and normalized to reference gene transcripts. (c) Cultures were treated for 24 h with
concentrations of a mixture of ceramides C16, C22, and C24:1, mimicking those detected in the plasma of MS patients with normal (Low) or high BMI (High) in the absence or
presence of the DNA methylation inhibitor, 5-aza-2′-deoxycytidine (5-aza). DNA was harvested and processed for Sequenom Mass Array EpiTyper, in order to quantify differential
methylation of CpGs (Y axis) at the indicated genomic locations (X axis). The gene name is shown on top of each graph. Overall methylation differences for the entire region of
interest for each gene were assessed using two-way ANOVA (*p b .05, ***p b .0001) (n = 3/group, n = 2 replicates/group). (d) Transcript levels of NRXN1, FZD7, and TP63 were
assessed using real time-PCR and normalized to the levels of thehousekeeping gene, RPLP0. Cer C16 groups were compared to Untreated groups using Student's t-test, while the High
and High +5-aza groups were compared to the Low group, using Dunnett's multiple comparisons test (*p b .05, **p b .01, ***p b .001) (n = 3 independent experiments, n = 3
biological replicates/experiment, n = 3 technical replicates/biological replicate).
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Fig. 7.Monocytes uniquely correlate with reduced brain volume in overweight/obese MS patients, who exhibit worsened disease course at the two-year follow up. (a) Brain volumetric
analysis was performed on T1-weighted images fromMRI scans and correlated with CD14+monocyte counts from fresh whole blood, which had been obtained by ﬂow cytometry, in a
primary MS cohort (n = 41), validation MS cohort (n= 80) and a healthy cohort (n = 48) using linear regression, p b .05 considered signiﬁcant. (b) Differences in the proportion of
patients who showed changes in T1 lesion load (ΔT1) b1 ml, between 0 and 1 ml, and N1 ml during a 2 year period, between MS patients with normal or high BMI were assessed by
chi-squared test (*p b .05). (c) Differences in the proportion of patients who had disease activity, deﬁned by clinical relapse or new lesions, during a 2 year period, between MS
patients with normal or high BMI were assessed by chi-squared test (*p b .05). (d) Change in EDSS in a 2 year period was categorized as better (b−0.5), same (−0.5 to 0.5), or worse
(N0.5) and correlated with BMI using ordinal regression, p b .05 considered signiﬁcant.
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tures with a cocktail of ceramides resembling those found in MS pa-
tients with high or normal BMI. DNA hypermethylation (Fig. 6C) and
reduced transcript levels (Fig. 6D) were only detected in cells exposed
to ceramide concentrations equivalent to those found in the high BMI
group of MS patients, and the effect was prevented by the presence of
pharmacological inhibitors of DNAmethylation. Of note, despite the oc-
currence of a sizeable ceramide-dependent DNA hypermethylation of
NRXN1 at CpG +50,201,389, its transcript levels were not fully rescued
by co-treatment with 5aza. This could be in part explained by a more
complex regulation of this gene transcript possibly relying on additional
epigenomic repressive marks. Overall these results further strengthen
the link between the elevated plasma ceramide levels detected in MS
patients with high BMI and DNA hypermethylation of genes negatively
regulating cell proliferation in monocytes.3.6. High monocytic counts, decreased brain volume and worsened disabil-
ity in MS patients with high BMI
The potential link between monocytes and neurological disability in
MS patients with high BMIwas initially suggested by a negative correla-
tion between MRI brain volume measurements and monocyte cell
counts in our discovery cohort at baseline, a ﬁnding that was conﬁrmed
in the validation cohort of therapy naïve MS patients and was absent in
the healthy cohort (Fig. 7A). These results led to the hypothesis that MS
patientswith high BMIwould be characterized by greater brain atrophy,
a correlate and predictor of clinical disability [77–79].While differences
in brain volume between the two-year follow-up compared to baseline
could not be calculated due to incomparable sequences between the
two time points, we were able to measure changes in T1 lesion volume
(ΔT1 = T1 lesion volume at follow-up – T1 lesion volume at baseline),
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ble correlate of brain atrophy and clinical disability [77,80–83]. While
themajority of patients showed small positive changes in T1 lesion vol-
ume (0 ≤ ΔT1 ≤ 1), suggestive of stable status or mild worsening of T1
lesion load, a greater proportion of MS patients with high BMI (n =4/13) had more severe worsening (ΔT1 N 1) than those with normal
BMI. Conversely, a greater proportion of MS patients with normal BMI
(n = 2/15) showed better outcome at the two-year follow-up (ΔT1 b
0) (Fig. 7B). Similar trends were identiﬁed for disease activity (deﬁned
as either new MRI activity or clinical relapse) and clinical disability (as
406 K. Castro et al. / EBioMedicine 43 (2019) 392–410measured by EDSS), irrespective of therapy (Fig. S6). A signiﬁcantly
greater portion of high BMI MS patients (n = 12/25) compared to
those with normal BMI (n = 4/22) showed signs of increased disease
activity within the two-year period (Fig. 7C). Worsened disability in
the high BMI group, was also suggested by ordinal logistic regression
of the differential clinical score (after adjusting for age, sex, and race),
which was calculated by comparing the EDSS score at the two-year
follow-up to that at baseline (ΔEDSS = EDSS at follow-up – EDSS at
baseline) and deﬁned as better (bΔ-0.5), same (−Δ0.5 to Δ0.5) or
worse (NΔ0.5) (Fig. 7D). Overall these data indicate the association be-
tween high BMI andworse disease course, both with respect to ongoing
inﬂammatory disease activity and overall level of clinical disability.3.7. Elevated monocytic counts and worse disease course in experimental
MS in mice on high fat diet
To further validate the relationship between body mass, number of
monocytes and clinical disability, we immunizedmicewith amyelin ol-
igodendrocyte glycoprotein peptide (MOG35–55) to induce Experimen-
tal Autoimmune Encephalitis (EAE), a model of MS. Body weight pre-
induction was increased by feeding mice a high fat diet, while controls
were kept on a low-fat diet. After 5 weeks on high fat diet, mice gained
weight compared to controls, while retaining normal blood levels of
glucose (Fig. S7A). Immunization was performed after the 5 weeks of
diet, which was also kept constant for the entire duration of the exper-
iment (Fig. 8A).Micewere scored on a clinical scale of 0 to 5 to provide a
quantitative measurement of the ascending paralysis over time. Mice
with higher body mass at the time of induction (HFD-EAE) showed
greater clinical disability compared to controls (LFD-EAE), and this
was supported by a signiﬁcantweight change from theweight at immu-
nization to the peak of disease (Fig. 8B-C). While the overall disease du-
ration did not differ between the two groups, the maximum clinical
score was higher in mice with higher body weight, thereby suggesting
greater disease severity (Fig. 8D). Comparative histological analysis at
the peak of disease revealed reduced Fluoromyelin+ (FM+) area and a
trend for reduced Neuroﬁlament H+ (NFH+) area in the spinal cord of
mice with higher body mass, indicative of increased demyelination
and axonal loss, respectively (Fig. 8E). The greater clinical disability
and CNS lesion load detected in high fat diet mice were associated
with increased monocytic inﬁltration, as measured by Iba1+CD45+
area within the demyelinated lesions, further supporting the suggested
correlation between higher monocytic numbers and myelin and axonal
loss (Fig. 8F). Notably, non-immunized mice fed a high fat diet for
5 weeks were characterized by increased levels of ceramide species in
spinal cord (data not shown) and a trend for increased monocytic inﬁl-
tration, further supporting a link between elevated ceramides and
monocyte counts (Fig. S7B\\C). DNA methylation levels, as assessed
by 5mc intensity, were also higher in Iba1+ cells in high fat diet EAE
mice compared to controls, supporting the association observed in pa-
tients (Fig. 8G). Thus, these results further support the link between
greater disease severity and higher body weight in animal models of
MS.Fig. 8. High-fat diet fed mice show increased monocytic inﬁltration and greater neurological d
(LFD) or high-fat diet (HFD) for 5 weeks, and then immunized with 200 ng MOG35–55 using a
scores indicating increased clinical disability (black = LFD-EAE mice, gray = HFD-EAE mice)
time point using Mann-Whitney U test, respectively (*p b .05, **p b .01) (n = 15/group). (c
point and differences between LFD-EAE and HFD-EAE mice were evaluated by Sidak's multip
maximum EAE score were also used to evaluate differences in disease course and statistical a
at the peak of disease and spinal cord tissue sectioned for histological analysis. Spinal cor
Neuroﬁlament H (NFH) to stain axons. Images were acquired using the Zeiss LSM 800 confoca
quantiﬁed as the area of FM or NFH positivity, respectively, in relation to the whole spinal c
monocytes/activated microglia (Iba1+ CD45+) and leukocytes (CD45+) and counterstained
the 20× objective (scale bar = 25um). Iba1 + CD45+ area and CD45+ area was quantiﬁe
leukocytes, respectively, and was calculated as a percentage in relation to the total spinal cor
levels in monocytes. Images were acquired using the Zeiss LSM 800 at 63× (scale bar = 10
Statistical differences between LFD-EAE (white) andHFD-EAE (gray) groupswere assessed by S4. Discussion
This study identiﬁes amechanistic linkbetween high BMI, ceramide-
induced DNAmethylation in monocytes and disease course in Multiple
Sclerosis patients and mouse models. Our data suggest that the higher
monocytic counts detected in high BMI MS patients compared to
those with normal BMI might be consequent to ceramide-dependent
hypermethylation of DNA on anti-proliferative genes, resulting in de-
creased expression levels, favoring proliferation. MS patients with
high BMI also showed greater disease activity andworsened clinical dis-
ability at the two-year clinical follow up visit. Previous studies reported
an association between obesity and increased pro-inﬂammatorymono-
cyte subsets [84–86]. While we did not detect this increase in healthy
controls, we cannot exclude the possibility that our inability to identify
differential monocytic counts in the control cohort could be due to lack
of sufﬁcient power and possibly to the inclusion of several overweight
subjects. It is also worth mentioning that the fasting/feeding state, to
whichmonocytes are highly responsive [87], was not taken into consid-
eration in our study. The differential abundance of ceramide species de-
tected in MS patients with high BMI was not detected in healthy
individuals grouped by BMI within a similar range. This ﬁnding is in
agreement with previous results reporting elevated plasma ceramide
levels in obese subjects with metabolic disorders and diabetes
[88–91]. Overall, this cumulative evidence supports the concept of ele-
vated ceramide species in MS might be speciﬁc to the disease state, a
concept which deserves further investigation.
Ceramides belong to the family of sphingolipids, whose role has
been reported in a wide variety of pathological states, ranging from co-
lorectal and breast cancer [92–96] to dermatological conditions [97] and
osteoarthritis [98,99]. Compelling data on ceramides have been pub-
lished in patients with cardiovascular diseases [100] and the ratio of
speciﬁc ceramide species has been evaluated as an indicator of cardio-
vascular disease activity and a predictive index of clinical outcome
[101,102], thereby suggesting ceramides as better predictors of death
by cardiovascular diseases than other lipid biomarkers [38,39,103]. A se-
ries of lipidomic studies in patients with neurological disorders identi-
ﬁed differential abundance of ceramides in plasma and cerebrospinal
ﬂuid of patients with Parkinson's disease [104–107] or Alzheimer's dis-
ease [108,109]. The levels of these sphingolipids were associated with
the detection of early cognitive impairment [110,111] and increased
risk of disease development [112]. Elevated ceramide species, C16 and
C24, were also reported in the cerebrospinal ﬂuid [36] and plasma of pa-
tients with MS [37,72]. Our study is in agreement with these previous
ﬁndings, while providing evidence for additional mechanisms of action
for ceramides in MS. Besides the previously reported neurotoxic role of
ceramides [36],we propose a nuclear function for ceramides as inducers
of DNA hypermethylation on anti-proliferative genes in monocytes,
resulting in elevated monocytic cell counts. We also deﬁne the impor-
tance of BMI as an important determinant ofworsened clinical disability
in MS, a concept which deserves further investigation and validation by
other groups.
Ceramides are polar lipids formed by a sphingoid backbone conju-
gated to acyl-chains of different lengths and can be synthesized deeﬁcits in an experimental model of MS. (a) Female C57/bl6 mice were fed either a low-fat
protocol to induce EAE. (b) Ascending paralysis was graded on a scale of 0 to 5 with high
. Differences in EAE scores were evaluated between LFD-EAE and HFD-EAE mice at each
) Weight change from baseline (i.e. day of immunization) was calculated for each time
le comparisons test (**p b .01). (d) Area under the curve of the EAE disease course and
nalysis was performed using Mann-Whitney U test (*p b .05). (e-g) Mice were sacriﬁced
d sections were stained with Fluoromyelin (FM)to stain myelin and lesion areas and
l microscope and the 20× objective (scale bar = 50um). Myelin and axonal content were
ord area. Spinal cord sections were also stained with Iba1 and CD45 to mark peripheral
with DAPI, to identify nuclei. Confocal images were acquired using the Zeiss LSM 800 and
d within the lesion to enhance representation of peripheral monocytes and peripheral
d area. Spinal cord sections were stained with 5mc and Iba1 to assess DNA methylation
um). 5mc intensity was normalized to DAPI intensity in Iba1+ cells within the lesion.
tudent's t-test (*p b .05) (n=3mice/group, n= 2 sections/mouse, n= 3 images/section).
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lipids from damaged cells [113,114]. Importantly, their de novo synthe-
sis has been related to the type of fats in the diet as they can be gener-
ated from saturated, but not unsaturated, dietary fats [115]. In MS
patients, the immune-mediated destruction of the myelin membrane,
which is highly enriched in sphingomyelin [116] likely results in in-
creased recycling of this molecule into ceramide, which is consistent
with previously reported alterations of sphingolipids in post-mortem
studies on MS brains [34,35] and further supported by the negative
correlations between the gray matter-enriched C18 and the white
matter-enriched C24:1 [117] and brain volume. While the importance
of dietary saturated fats as a source of ceramides requires further inves-
tigation, the detection of differentially abundant ceramide species in the
plasma of MS patients highlights the contribution of immune-mediated
demyelination to the salvage pathway and provides an explanation for
the higher abundance of ceramides in high BMI patients as resulting
from the combination of de novo synthesis from dietary fats and
recycling of lipids from damaged myelin.
While the emphasis on the role of sphingolipids inMultiple Sclerosis
has principally focused on the role of sphingosine and its receptors
[33,118,119], this study addresses the mechanistic role of plasma
ceramides. Ceramides represent a class of bioactive lipids that has
gained recent interest due to their highly cell-speciﬁc effect on survival
and proliferation [120,121]. Our data identify DNA methylation
in monocytes as responsive to exogenous ceramides in a dose-
dependent manner, leading to DNA hypermethylation and transcrip-
tional repression of negative regulators of cell proliferation and overall
increased proliferation. These ﬁndings are consistent with a model by
which ceramide levels (either synthesized de novo from dietary lipids
or recycled from damaged myelin) signal to the nucleus of monocytes
and modify their epigenome and transcriptional program. The concept
of lipid mediators as signals for the induction of genome-wide epige-
netic changes is consistent with recent studies in cultured monocytes
treated with free fatty acids in vitro [66–70]. However, the detection
of nuclear and cytoplasmic localization of ceramide, after uptake in
monocytes, suggests that, besides methylation, ceramide could modu-
late the activity in other manners [122]. Several mechanisms of action
for these sphingolipids have been proposed, including the modulation
of intracellular signaling pathway, due to reorganization of lipid rafts
on the plasma membrane [123], or their effect on bioenergetics, due
to incorporation into the mitochondrial membrane with consequently
impact its integrity and function [124,125]. Future studies are needed
to address the role of ceramides with acyl chains of different length on
subcellular localization and function.
Finally, the correlation between increasedmonocytic counts and re-
duced brain volume in MS patients with high BMI highlighted the im-
portance of monocytes in neurodegeneration, a concept which we
validated in mice by manipulating their weight with a high fat diet
and by using an experimental model of immune-mediated demyelin-
ation. Overall, the functional relationship between increased monocyte
counts and neurodegeneration is an emerging concept in neuroscience
[126–128]. InMS, this concept is supported by the detection of inﬁltrat-
ing monocytes/macrophages at sites of contact with damaged neurons
as detected in post-mortem human MS brains and related murine
models [129–132]. It is also consistent with the protective effect of
their depletion on axonal damage in preclinical models of MS [133].
This study builds on these ﬁndings and identiﬁes ceramide-induced
changes in DNAmethylation as themechanistic linkwhich underlies in-
creased monocytic cell counts in MS patients with high BMI.
A potential limitation of the current study is the relatively small size
of the patient cohort, which was dictated by stringent inclusion/exclu-
sion criteria and by additional difﬁculties in performing longitudinal
studies. While we consider our results in the discovery cohort very ex-
citing and mechanistic, we acknowledge that the potential consider-
ation of ceramide levels as biomarkers for disease progression in MS
would require validation of our ﬁndings by other groups using largercohorts with a longitudinal and/or cross-sectional design. It will also
be important to evaluate the effectiveness of dietary intervention
(with an emphasis on the reduction of speciﬁc classes of saturated
fats), as potential modulator of plasma ceramide levels and possibly of
disease course in MS patients.
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